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根据实验目的将 48 只大鼠随机分为两组，其中每组又分为三小组： 
1）预防性西那卡塞干预组：假手术组（Sham 组，n=8）、5/6 肾切除大鼠对
照组（Nx 组，n=8）、西那卡塞干预组（Cina 组，n=8），于肾大部分切除术后 1
周内给予西那卡塞干预。 
2）西那卡塞干预组：假手术组（Sham 组，n=8）、5/6 肾切除大鼠对照组（Nx
组，n=8）、西那卡塞干预组（Cina 组，n=8），于肾大部分切除术 4 周眼球采血
后检测肾功能后再给予西那卡塞干预。 
术后对各小组均给于高磷饮食加重 SHPT，其中给药组均给予西那卡塞






















组较 Nx 组 iPTH 均降低（P 均＜0.05）。 
2） 免疫组化结果显示，西那卡塞干预组 PCNA 表达均较 Nx 组表达降低（P 均
＜0.05），而西那卡塞干预组较 Nx 组表达降低（P 均＜0.05）。 
3） 各 Nx 组大鼠 Scr、Urea 同 sham 组相比，肾功能下降明显（P 均＜0.05）,而
西那卡塞干预组较 Nx 组肾功能可明显改善（P 均＜0.05）。 
4） 各 Nx 组大鼠 GSI 和 TIS 评分同 sham 组相比（P 均＜0.05），其中实验一中
Cina 组同 Nx 组相比 TIS 评分下降 (P 均＜0.05），实验二中同 Nx 组相比，
Cina 组 GSI 和 TIS 评分下降(P 均＜0.05）。 
5） 各 Nx 组大鼠 FGF23 均较各 Sham 组明显升高（P 均＜0.05），西那卡塞干预
组 FGF23 较 Nx 组均降低（P 均＜0.05）。 
结论 
高磷饮食可以加重 5/6 大鼠继发性甲状旁腺功能亢进；盐酸西那卡塞可以缓

















Backgroud   
With the development of chronic kidney disease (CKD), the CKD patients can 
show the imbalance of calcium and phosphate，deficiency of vitamin D，the rise of 
parsthyroid homone and fibroblst growth factor 23 in the early stage of kidney injury. 
However, those above mentioned factors will result in secondary hyperparathyroidism 
and kidney demage. Parathyroid hyperplasia can be prevented by calcium-sensing 
receptor (CaSR) activation which is applied to patients in dialysis. In order to study 
whether cinacalcet can prevent the development of secondary hyperparathyroidism, 
mineral metabolic disorder and kidney injury, we established a rat model with 5/6 
renal resection combinding with high phosphorus diet, then gave cinacalcet before 
and after the rat renal failure, and then observe the effect of this drug preventing and 
controlling secondary hyperparathyroidism and kidney injury in the uremic rat. 
Methods 
According to the aim of this experiment, animals were averagely placed into one of 
the following six groups at random and two separate experiments were performed 
with cinacalcet. 
(1)Prophylactic treatment with cinacalcet: Sham-operated group（Sham group, n=8）; 
5/6-nephrectomized group（Nx group, n=8）; cinacalcet group （Cina group, n=8）. 
(2)Cinacalcet treatment with established CKD: Sham-operated group（Sham group, 
n=8）; 5/6-nephrectomized group（Nx group, n=8）; cinacalcet group（Cina group, 
n=8）. 
All the animals had high phosphorus diet after operation and the treatment groups 
(i.e. cinacalcet groups) were supplied with cinacalcet 10mg/Kg/day for six weeks. 
Meanwhile, their blood samples were taken at 4th, 6th and 10th weeks after operation 
(Cina group were taken 4 h post-treatment at the times) to determine blood 















25(OH)D3, phosphorus and calcium]. Parathyroid proliferating cell nuclear antigen 
(PCNA) and the renal histopathological changes were determined in tissue samples 
obtained at sacrifice.  
Results  
(1) The level of serum iPTH in Nx groups were significantly increased than in Sham 
group (P＜0.05), Cinacalcet decreased serum iPTH levels (P＜0.05).  
(2) immunohistochemical results show that PCNA expression in the parathyroid gland 
of Nx group were significantly increased than in the Sham group (P＜0.05), while 
the Cinacalcet group lower than the Nx group (P＜0.05). 
(3) The level of Urea, Scr were in Nx groups significantly increased than in Sham 
group (P＜0.05), Cinacalcet decreased serum Scr, Urea (P＜0.05). 
(4) The score of GSI and TIS in Nx groups were significantly increased than in Sham 
group (P＜0.05), In the first experiment, the score of TIS in the cinacalcet 
treatment group lower than the Nx group (P＜0.05). In the second experiment, 
both of score in the cinacalcet treatment group lower than the Nx group (P＜
0.05). 
(5) The level of serum FGF23 in Nx groups were significantly increased than in Sham 
group (P＜0.05), Cinacalcet decreased serum FGF23 levels (P＜0.05). 
Conclusion 
High phosphorus diet can aggravate the secondary hyperparathyroidism of 
5/6-nephrectomized rats. Cinacalcet HCl can prevent and reverse the development of 
secondary hyperparathyroidism, renal injury and the rise of FGF23 in the 
5/6-nephrectomized rodent model. 
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英文缩写 全称 中文名称 
CKD Chronic kidney disease 慢性肾脏病 
ESRD End stage renal disease 终末期肾病 
SHPT Secondary hyperparathyroidism 继发性甲状旁腺功能亢进 
PTH Parathyroid hormone 甲状旁腺激素 
FGF23 Fibroblst growth factor 23 成纤维生长因子 
PG Parathyroid gland 甲状旁腺 
CaSR Calcium-sensing receptor 钙敏感受体 
CVD CKD-associated cardiovascular 
disease 
慢性肾脏病相关心血管疾病 




VSMC  vascular smooth muscle cell 血管平滑肌细胞 
VC Vascularcalcification 血管钙化 
PBS     Phosphate buffered saline 磷酸盐缓冲液 
DAB Diaminobenzidine 二氨基联苯胺 
SCr Serumcreatinine 血肌酐 
BUN Ureanitrogen 尿素氮 
TRPV5 Transient receptor potential 
vanilloid 
瞬时性受体电位香草精受体 5 
Cina Cinacalcet 西那卡塞 
GFR Glomerular filtration rate 肾小球滤过率 
GSI Glomerulosclerosis index 肾小球硬化指数 















PCNA proliferating cell nuclear antigen 增殖细胞核抗原 
RANKL Receptor Activator for Nuclear 
Factor-κ B Ligand 
核因子 κ B 受体活化因子配体 































继发性甲状旁腺功能亢进 (secondary hyper-parathyroidism，SHPT) CKD 患
者体内各种矿物质代谢紊乱会刺激甲状旁腺分泌过多的 PTH 并形成甲状旁腺增
生/腺瘤，即发生了 SHPT。随着肾小球滤过率 (glomerular filtration rate，GFR) 的
下降，SHPT 的发生率会逐渐升高。在 GFR 为 60～90ml/min/1.73m 时，慢性肾






原纤维蛋白及较多的 RANKL 配合基。这给临床治疗 SHPT 造成困难[4]。在临床















PTH 为基准，301-450 pg/mL 的 PTH 显示出较高的全因死亡率，而达到 600pg/mL
者死亡率则更高，超过 600pg/mL 者心血管的死亡的风险和心血管的住院率增加，




SHPT 的进展尤为重要。由于 SHPT 患者以分泌过多 PTH 及甲状旁腺的增生为特
征，因此在控制钙磷代谢紊乱的同时有效降低 PTH 水平、阻止甲状旁腺细胞增






泌 ；而 Ca2+ 则是通过结合甲状旁腺钙受体细胞外结构域，负反馈于甲状旁腺，





5/6 肾切除大鼠是目前公认的较好的慢性肾衰竭大鼠模型，该模型术后 1 周
即出现一过性的血浆及尿素氮的升高，此时期称为为急性肾衰竭或急性失代偿




实在大鼠 5/6 肾切除术后给予其高磷饮食会加重 SHPT[9],研究表明给予 5/6 肾切
除大鼠加高磷饮食 2 周后即可出现甲状旁腺增生，表现为甲状旁腺体重量与大鼠
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